Our Successes

Client feedback

We support 8 out of 10 of the top pharma and 4 out of 5 of the top agchem companies worldwide in provision of drug metabolites. We are proud of our excellent reputation in the industry and take pride in doing all we can to achieve successful project outcomes for our clients.

Read some of our client feedback below.

Contact us at mail@hyphadiscovery.co.uk to find out how we can support your project.

“The services conducted by Hypha allowed Alkermes to enhance our “Late Stage Functionalization” efforts to rapidly expand our SAR understanding inside projects. In particular, the PolarExplorer work allowed facile generation of hydroxylated compounds possessing a complex molecular core.
We look forward to engaging Hypha in the future because their team is professional, and their services complement our internal synthetic efforts for delivering new molecules.“

 Brian Aquila, Director of Medicinal Chemistry, Alkermes, Waltham MA, USA

“Hypha Discovery did a fantastic job synthesizing N- and O- glucuronides of our clinical stage drug substance. The project updates were detailed, our questions were answered in a timely manner, and the overall timeline was maintained. Hypha was highly recommended to us and I would not hesitate to recommend them to a colleague.”

 Joshua Day Ph.D, Director of Chemistry, Crestone, Inc., Colorado, USA

“Hypha Discovery was a huge help to our drug development timeline, when an ADME study revealed significant metabolites that were challenging to synthesize chemically. Hypha was able to rapidly reproduce the metabolites to confirm chemical structure, and then scale up to support nonclinical testing and bioanalytical method development, with far greater speed than chemical synthesis could achieve. The Hypha people were very pleasant to work with and the material they produced was of very high quality, which rounded out an overall great experience. I would recommend them without reservation.”

Senior VP, Pharmaceutical Sciences, US Pharma company

“Hypha Discovery has been a valuable metabolite ID partner. Hypha have provided biotransformation, metabolite purification and structure elucidation answers to some of our most challenging metabolism and metabolite ID problems. We really appreciate the breadth of expertise available at Hypha Discovery and will definitely reach out for future work.”

Director of DMPK, US Pharma Company

“We approached Hypha Discovery for the preparation of 10-50 mg quantities of two API metabolites that had proven difficult to synthesise chemically. The project was highly successful, combining beautifully executed multi-disciplinary science with clear and responsive communications; the collaboration was a genuine pleasure. I have no hesitation in recommending Hypha to others for metabolite generation and scale-up.”

Head of CMC, UK Pharma Company

“We would like to mention that it has been a pleasure to work with Hypha in this project. We are really satisfied with how the collaboration has progressed, reaching the defined goals and timelines in a very efficient manner. Access of hydroxylated compounds through PolyCYPs has saved our company time and resources. We are sure that we will have more opportunities to work together in the future.”

Program Leader, European Pharma Company

Hypha Discovery came highly recommended and we subsequently contracted with Hypha to extract and purify metabolites out of rabbit urine.  As they were so successful with that extraction, we again requested help for a second program to extract metabolites from human urine and/or synthesize/biosynthesize 3 metabolites. As expected, Hypha has been successful preparing these metabolite reference standards along with structural elucidation and certificates of analysis. In addition, synthesis of one of the metabolites had been attempted at 2 other labs without success; however, Hypha was able to synthesize this difficult metabolite which allowed us to do further evaluations on the metabolite.

Hypha has exceeded our expectations and is now a ‘go to’ lab for biosynthesis/synthesis/purification. Hypha’s team was a pleasure to work with and our complicated projects were handled with expertise and professionalism.  Their excellent scientific communication and project data were extremely comprehensive and we received updates throughout the process. We will definitely be Hypha Discovery clients for life”

Head of Toxicology/DMPK, US Pharma company

“It has been a pleasure working with Hypha for this project. The knowledge gained has a substantial impact on the Phase 3 program. It is great to understand your platform and how it can assist us with metabolites or diversification of new discovery compounds.”

Director of CMC, US Pharma company

“We sure appreciate working with Hypha who helped us prepare larger quantities of a difficult-to-synthesize metabolite of praliciguat.

Dr. Jim Sheppeck, Discovery Program Leader, Cyclerion Therapeutics, Cambridge MA, USA

“We worked with Hypha discovery to synthesize metabolites via a chemical approach in enough quantities for pharmacology studies for one of our products. Hypha has well understood our request and has provided a very good quality of service in time, in quantity and quality with the needed level of regular communication. We will work certainly with them in the future and will recommend them.

Dr. Laure Navarre, Director Process Chemistry, Poxel, France


“Upon hearing of Hypha’s expertise in microbial transformation, we were intrigued to explore whether it might be useful for exploring the incorporation of polar groups into lead molecules in ways that were independent of synthetic considerations. We piloted two compounds from two separate projects with Hypha, choosing examples that we knew to have moderate microsomal stability. We were very pleasantly surprised at the productive outcome where microbial incorporation of a hydroxyl group on a t-butyl substituent boosted the potency of a kinase inhibitor 20-fold, such that the LLE was increased by an extraordinary 2.6 units.”

Will Watkins, VP Medicinal Chemistry, Gilead Sciences, San Francisco, USA


“We contacted Hypha Discovery to generate specific phase I and phase II metabolite standards in sufficient quantities and purity to allow structural confirmation and quantitation. Hypha exceeded expectations, providing 60mg of a phase I metabolite and over 100mg of a phase II metabolite at high purity. Hypha’s team was a pleasure to work with and communicative and responsive throughout the process. We will undoubtedly be working with Hypha Discovery in the future.”

Jason Boer, Associate Director, Incyte Corporation, Wilmington, USA


“We have used Hypha Discovery to provide samples of several pesticidal natural products by fermentation. We find them good people to work with. They provide a flexible and reliable service, meeting agreed deadlines, and so far have always provided us with the target compounds. We are pleased to recommend Hypha Discovery. Certainly we plan to continue to work with them.”

Dianne Irwin, Principal Research Chemist, Syngenta, Jealott’s Hill, UK

One of our lead programs at Cypralis required a natural product fermentation process as the starting point and we turned to Hypha Discovery to help with improvements to the process.  Working closely with the Hypha scientists, under funding from an Innovate UK award, the producing strain was modified to yield over 5-fold more of our desired starting material and with a cleaner purity profile.  These modifications will enable Cypralis to transition the process to large scale to support our pre-clinical studies.  Working with the Hypha group has been a very rewarding experience and we look forward to future collaborations.”

Dr. Michael Peel, Chief Scientific Officer, Cypralis Ltd., Cambridge, UK


“When the need to generate, and characterize, oxidative metabolites of a complex natural product emerged, Scynexis recognized that direct synthesis may be difficult and instead turned to Hypha Discovery to explore biosynthetic  opportunities.  The Hypha team was extremely professional in their approach to the problem and rapidly identified organisms that produced the desired metabolites.  The group then went on to scale-up the biosynthesis such that full structural characterization was achieved.  Scynexis appreciates the problem solving abilities of the Hypha team and will certainly turn to their expertise for further projects when needed.”

Dr. David Angulo, Chief Medical Officer, Scynexis Inc, Jersey City, NJ, USA

Phenex Logo

“We commissioned Hypha to produce 50-200 µg of an oxidative metabolite where structural details were ambiguous. They provided 1mg of highly pure metabolite enabling full structure elucidation.”

Manfred Birkel, Head of DMPK, Phenex Pharmaceuticals AG, Heidelberg, Germany

Sigmoid Pharma_logo

“Hypha’s biotransformation service made available materials important to support our innovative drug delivery and development programs. Their expertise and professionalism made them easy to work with and we would gladly do so again if the occasion arises.”

Dr Ivan Coulter, CEO Sigmoid Pharma, Ireland

In the context of a customer project, Selcia requested Hypha Discovery to produce a target molecule by microbial fermentation in sufficient quantity for an exploratory chemistry programme. Not only did Hypha Discovery deliver to our full satisfaction, as an added benefit we obtained a strain with improved productivity and reproducible protocols for fermentation, extraction, and purification of the target molecule. This, in turn, resulted in a highly satisfied Selcia customer. Should the occasion arise again, I will certainly turn to Hypha Discovery first.”

Hans Fliri, Managing Director, Selcia, Essex, UK


“Hypha Discovery very efficiently purified and identified bioactive molecules from microbial extracts. The work was on behalf of major pharma and agchem companies, and Hypha Discovery certainly didn’t let us down.

Jean-Marc Seng, Managing Director, BIOtransfer, Montreuil, France

Back to Top